Change of bone quality during endocrine therapy for prostate cancer

Change of bone quality during endocrine therapy for prostate cancer - Change of bone quality during endocrine therapy for prostate cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000019808

Enrollment

Registered

2017-01-01

Start date

2016-02-17

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate cancer

Interventions

None listed

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: 1) Pathologically diagnosed prostate cancer 2) Planned androgen deprivation therapy for more than 1 year as initial therapy.

Exclusion criteria

Exclusion criteria: 1) Prior history of androgen deprivation therapy 2) Prior history of steroidal therapy

Design outcomes

Primary

Measure	Time frame
Change of bone quality markers	—

Secondary

Measure	Time frame
Change of BMD, incidence of fracture, QOL	—

Countries

Japan

Contacts

Public ContactTakahiro Kimrua

Jikei University School of Medicine Department of Urology

tkimura@jikei.ac.jp0334331111

Outcome results